| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $68,813 | 3 | 100 |
| Mahmood Nadir | President | 0 | $0 | 1 | $11,693 | $-11,693 |
| HASTINGS PAUL J | Chief Executive Officer | 0 | $0 | 2 | $57,119 | $-57,119 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Over the last 12 months, insiders at Nkarta, Inc. have bought $0 and sold $68,813 worth of Nkarta, Inc. stock.
On average, over the past 5 years, insiders at Nkarta, Inc. have bought $46.5M and sold $1.32M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000,000 shares for transaction amount of $30M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
| 2026-01-15 | Sale | HASTINGS PAUL J | Chief Executive Officer | 26,046 0.0387% | $2.07 | $53,915 | +12.24% | |
| 2026-01-15 | Sale | Mahmood Nadir | President | 5,649 0.0084% | $2.07 | $11,693 | +12.24% | |
| 2025-06-18 | Sale | HASTINGS PAUL J | Chief Executive Officer | 1,790 0.0025% | $1.79 | $3,204 | +10.44% | |
| 2025-01-15 | Sale | HASTINGS PAUL J | Chief Executive Officer | 17,378 0.0241% | $2.20 | $38,232 | -12.50% | |
| 2025-01-15 | Sale | Shook David | See Remarks | 8,638 0.012% | $2.20 | $19,004 | -12.50% | |
| 2025-01-15 | Sale | Hager Alicia J. | Chief Legal Officer | 9,584 0.0133% | $2.20 | $21,085 | -12.50% | |
| 2025-01-15 | Sale | Brandenberger Ralph | Chief Technical Officer | 7,447 0.0103% | $2.20 | $16,383 | -12.50% | |
| 2025-01-15 | Sale | Levin Alyssa | See Remarks | 5,838 0.0081% | $2.20 | $12,844 | -12.50% | |
| 2024-07-16 | Sale | Hager Alicia J. | Chief Legal Officer | 3,396 0.0065% | $8.00 | $27,168 | -70.63% | |
| 2024-06-18 | Sale | HASTINGS PAUL J | Chief Executive Officer | 1,770 0.0022% | $5.60 | $9,912 | -52.85% | |
| 2024-06-18 | Sale | Trager James | Chief Scientific Officer | 456 0.0006% | $5.60 | $2,554 | -52.85% | |
| 2024-06-18 | Sale | Shook David | Chief Medical Officer | 456 0.0006% | $5.60 | $2,554 | -52.85% | |
| 2024-06-18 | Sale | Hager Alicia J. | Chief Legal Officer | 727 0.0009% | $5.60 | $4,071 | -52.85% | |
| 2024-06-18 | Sale | Brandenberger Ralph | Chief Technical Officer | 229 0.0003% | $5.60 | $1,282 | -52.85% | |
| 2024-03-27 | RA CAPITAL MANAGEMENT, L.P. | 3M 5.4767% | $10.00 | $30M | -58.16% | |||
| 2024-03-27 | George Simeon | director | 2M 3.6511% | $10.00 | $20M | -58.16% | ||
| 2024-03-01 | Sale | Brandenberger Ralph | Chief Technical Officer | 8,367 0.0167% | $12.51 | $104,671 | -59.03% | |
| 2024-02-12 | Sale | Trager James | Chief Scientific Officer | 4,143 0.0088% | $12.00 | $49,716 | -52.34% | |
| 2024-01-16 | Sale | HASTINGS PAUL J | Chief Executive Officer | 9,697 0.02% | $8.74 | $84,752 | -31.65% | |
| 2024-01-16 | Sale | Trager James | Chief Scientific Officer | 4,560 0.0094% | $8.74 | $39,854 | -31.65% |
| HASTINGS PAUL J | Chief Executive Officer | 390023 0.5491% | $971,157.27 | 0 | 11 | |
| Mahmood Nadir | President | 167727 0.2361% | $417,640.23 | 0 | 10 | |
| RA CAPITAL MANAGEMENT, L.P. | 10050818 14.1502% | $25.03M | 3 | 0 | <0.0001% | |
| GLAXOSMITHKLINE PLC | 3150732 4.4358% | $7.85M | 1 | 0 | <0.0001% | |
| MAKOWER JOSHUA | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| New Enterprise Associates 15, L.P. | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| Makhzoumi Mohamad | 10 percent owner | 2902115 4.0858% | $7.23M | 1 | 0 | <0.0001% |
| Novo Holdings A/S | 10 percent owner | 2793865 3.9334% | $6.96M | 1 | 0 | <0.0001% |
| George Simeon | director | 1548341 2.1799% | $3.86M | 2 | 0 | <0.0001% |
| Flynn James E | director | 1209936 1.7034% | $3.01M | 1 | 0 | <0.0001% |
| Shook David | See Remarks | 190955 0.2688% | $475,477.95 | 0 | 6 | |
| Trager James | Chief Scientific Officer | 150959 0.2125% | $375,887.91 | 0 | 10 | |
| Hager Alicia J. | Chief Legal Officer | 146735 0.2066% | $365,370.15 | 0 | 6 | |
| Brandenberger Ralph | Chief Technical Officer | 124796 0.1757% | $310,742.04 | 0 | 14 | |
| Levin Alyssa | See Remarks | 102662 0.1445% | $255,628.38 | 0 | 1 | |
| Rajangam Kanya | Chief Medical Officer | 0 0% | $0 | 0 | 1 |
$18,994,888 | 46 | 88.59% | $195.35M | |
$6,578,958 | 42 | 10.77% | $151.74M | |
$16,259,194 | 41 | 120.51% | $160.79M | |
$1,323,997 | 34 | 0.21% | $180.62M | |
$2,402,219 | 34 | 24.09% | $171.5M | |
$18,752,549 | 33 | -28.39% | $194.58M | |
$47,292,212 | 27 | -28.21% | $149.96M | |
$110,580 | 16 | 14.52% | $177.82M | |
Nkarta, Inc. (NKTX) | $448,999,793 | 15 | -19.99% | $176.86M |
$245,302 | 15 | -4.08% | $166.3M | |
$4,701,608 | 14 | -4.34% | $168.08M | |
$12,794,774 | 11 | -26.81% | $198.67M | |
$6,847,110 | 9 | 5.96% | $210.86M | |
$13,919,584 | 9 | -30.43% | $168.64M | |
$119,637,899 | 7 | -18.65% | $198.8M | |
$556,839 | 5 | 13.42% | $153.03M | |
$6,049,986 | 4 | -8.38% | $168.86M | |
$12,750 | 2 | -39.73% | $177.88M | |
$63,731 | 1 | -19.50% | $190.35M |
| Increased Positions | 54 | +41.86% | 3M | +5.48% |
| Decreased Positions | 52 | -40.31% | 4M | -6.69% |
| New Positions | 26 | New | 1M | New |
| Sold Out Positions | 11 | Sold Out | 939,565 | Sold Out |
| Total Postitions | 131 | +1.55% | 58M | -1.21% |
| Ra Capital Management, L.P. | $20,206.00 | 15.22% | 10.81M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $13,194.00 | 9.94% | 7.06M | 0 | 0% | 2025-09-30 |
| Samsara Biocapital, Llc | $7,046.00 | 5.31% | 3.77M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $6,916.00 | 5.21% | 3.7M | -455,308 | -10.96% | 2025-09-30 |
| Nea Management Company, Llc | $6,674.00 | 5.03% | 3.57M | 0 | 0% | 2025-09-30 |
| Sr One Capital Management, Lp | $6,233.00 | 4.7% | 3.33M | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $5,423.00 | 4.08% | 2.9M | -398,066 | -12.07% | 2025-09-30 |
| Vanguard Group Inc | $4,660.00 | 3.51% | 2.49M | -62,565 | -2.45% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $3,898.00 | 2.94% | 2.08M | 0 | 0% | 2025-09-30 |
| Monaco Asset Management Sam | $3,686.00 | 2.78% | 1.97M | +387,538 | +24.48% | 2025-09-30 |